目的 探究達格列凈聯(lián)合利拉魯肽治療2型糖尿病患者的臨床效果。方法 收集2017年1月—2019年4月在鄭州人民醫(yī)院治療的2型糖尿病患者126例，隨機分為對照組（63例）和治療組（63例）。對照組口服鹽酸二甲雙胍片，0.5 g/次，3次/d，同時于睡前皮下注射利拉魯肽注射液0.6 mg，1周后根據(jù)患者腸道反應(yīng)增加至1.2 mg，1次/d。治療組早餐前口服達格列凈片，10 mg/次，1次/d；利拉魯肽注射液的用法同對照組。兩組患者治療時間均為3個月。觀察兩組患者臨床療效，同時比較治療前后兩組患者糖化血紅蛋白（HbA1c）、空腹血糖（FPG）、餐后2 h血糖（2 h PG）、體質(zhì)量指數(shù)（BMI）、白細胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、對纖溶酶原激活物抑制物-1（PAI-1）和胱抑素C（CysC）水平。結(jié)果 治療后，對照組和治療組臨床有效率分別為79.37%和93.65%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者HbA1c、FPG、2 h PG、BMI、IL-6、TNF-α、PAI-1、CysC均顯著降低（P<0.05），且治療組上述指標比對照組更低（P<0.05）。結(jié)論 達格列凈聯(lián)合利拉魯肽治療2型糖尿病患者效果顯著，且不增加不良反應(yīng)，降低發(fā)生糖尿病血管并發(fā)癥的風險。

Objective To explore the therapeutic effect of daglitam combined with liraglutide in treatment of type 2 diabetes mellitus. Methods Patients (126 cases) with type 2 diabetes mellitus in Zhengzhou People's Hospital from January 2017 to April 2019 were randomly divided into control (63 cases) and treatment (63 cases) groups. Patients in the control group were po administered with Metformin Hydrochloride Tablets, 0.5 g/time, three times daily, at the same time, they were hypodermic injection administered with 0.6 mg of Liraglutide Injection, and the dose was increased to 1.2 mg based on intestinal reaction, once daily. Patients in the treatment group were po administered with Dapagliflozin Tablets, 10 mg/time, once daily. The usage of Lalutide Injection was the same as that of the control group. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the levels of HbA1c, FPG, 2 h PG, BMI, IL-6, TNF-α, PAI-1, and CysC in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 79.37% and 93.65% respectively, and there were differences between two groups (P<0.05). After treatment, the levels of HbA1c, FPG, 2 h PG, BMI, IL-6, TNF-α, PAI-1, and CysC in two groups were significantly decreased (P<0.05), and these indicators in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion The treatment effect of daglitam combined with liraglutide in treatment of type 2 diabetes mellitus is remarkable, and it does not increase the incidence of adverse reactions and reduce the risk of diabetic vascular complications.

R977

河南省醫(yī)學科技攻關(guān)計劃聯(lián)合共建項目（2018020817）